董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Frédéric Triebel | 男 | Chief Scientific Officer and Executive Director | 70 | 86.44万 | 3246.44 | 2025-10-24 |
| Pete Meyers | 男 | Deputy Chairman and Non-Executive Director | 55 | 13.87万 | 953.48 | 2025-10-24 |
| Lis Boyce | 女 | Non-Executive Director | 61 | 14.48万 | 未持股 | 2025-10-24 |
| Marc Voigt | 男 | Chief Executive Officer, Chief Financial Officer and Executive Director | 52 | 106.47万 | 4160.53 | 2025-10-24 |
| Russell Howard | 男 | Non-Executive Chairman | 75 | 16.35万 | 未持股 | 2025-10-24 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Frédéric Triebel | 男 | Chief Scientific Officer and Executive Director | 70 | 86.44万 | 3246.44 | 2025-10-24 |
| Christian Mueller | 男 | Chief Development Officer | -- | 未披露 | 未持股 | 2025-10-24 |
| Stephan Winckels | 男 | Chief Medical Officer | -- | 未披露 | 未持股 | 2025-10-24 |
| Marc Voigt | 男 | Chief Executive Officer, Chief Financial Officer and Executive Director | 52 | 106.47万 | 4160.53 | 2025-10-24 |
| Deanne Miller | 女 | Chief Operating Officer and Company Secretary and General Counsel | 48 | 56.52万 | 1976.84 | 2025-10-24 |
董事简历
中英对照 | 中文 | 英文- Frédéric Triebel
-
Frédéric Triebel医学博士，Triebel博士是Immutep Limited的首席科学官兼首席医疗官，在完成对Immutep S.A.的收购后，自2014年12月起加入公司。Triebel博士是Immutep S.A.的科学创始人，曾担任Immutep S.A.-2001的科学2004年起任Immutep副院长及医务主任。在创办Immutep公司之前，他是巴黎大学免疫学教授。在巴黎大型癌症中心Gustave Roussy IGR研究所工作期间，他于1990年发现了LAG-3基因，并从那时起继续从事这一研究项目，确定了这一分子的功能和医学用途。他领导了IGR的一个研究小组，同时还参与了在I/II期免疫疗法试验中接受治疗的癌症患者的生物学随访。他在1991年至1996年期间担任一个INSERM股的主任。Triebel教授最初是作为临床血液学家接受培训的，他拥有免疫学博士学位（巴黎大学），并成功开发了免疫遗传学和免疫疗法方面的多个研究项目，导致超过153项出版物和31项专利。
Frédéric Triebel,founded Immutep S.A. in 2001 and served as its Scientific and Medical Director from 2004. He was appointed as Chief Medical Officer and Chief Scientific Officer following the acquisition of Immutep S.A. in December 2014. Prof. Triebel was appointed as a Director on September 13, 2022 and is currently Chief Scientific Officer of the Company. Before starting Immutep S.A., he was Professor in Immunology at Paris University. While working at Institute Gustave Roussy (IGR), a large cancer center in Paris, he discovered the LAG-3 gene in 1990 and continued working on this research program since then, identifying the functions and medical Immutep Limited efulness of this molecule. He headed a research group at IGR while also being involved in the biological follow-up of cancer patients treated in Phase I/II immunotherapy trials. He was Director of an INSERM Unit from 1991 to 1996. First trained as a clinical hematologist, Prof. Triebel holds a Ph.D. in immunology (Paris University) and successfully developed several research programs in immunogenetics and immunotherapy, leading to 156 publications and 59 patents. - Frédéric Triebel医学博士，Triebel博士是Immutep Limited的首席科学官兼首席医疗官，在完成对Immutep S.A.的收购后，自2014年12月起加入公司。Triebel博士是Immutep S.A.的科学创始人，曾担任Immutep S.A.-2001的科学2004年起任Immutep副院长及医务主任。在创办Immutep公司之前，他是巴黎大学免疫学教授。在巴黎大型癌症中心Gustave Roussy IGR研究所工作期间，他于1990年发现了LAG-3基因，并从那时起继续从事这一研究项目，确定了这一分子的功能和医学用途。他领导了IGR的一个研究小组，同时还参与了在I/II期免疫疗法试验中接受治疗的癌症患者的生物学随访。他在1991年至1996年期间担任一个INSERM股的主任。Triebel教授最初是作为临床血液学家接受培训的，他拥有免疫学博士学位（巴黎大学），并成功开发了免疫遗传学和免疫疗法方面的多个研究项目，导致超过153项出版物和31项专利。
- Frédéric Triebel,founded Immutep S.A. in 2001 and served as its Scientific and Medical Director from 2004. He was appointed as Chief Medical Officer and Chief Scientific Officer following the acquisition of Immutep S.A. in December 2014. Prof. Triebel was appointed as a Director on September 13, 2022 and is currently Chief Scientific Officer of the Company. Before starting Immutep S.A., he was Professor in Immunology at Paris University. While working at Institute Gustave Roussy (IGR), a large cancer center in Paris, he discovered the LAG-3 gene in 1990 and continued working on this research program since then, identifying the functions and medical Immutep Limited efulness of this molecule. He headed a research group at IGR while also being involved in the biological follow-up of cancer patients treated in Phase I/II immunotherapy trials. He was Director of an INSERM Unit from 1991 to 1996. First trained as a clinical hematologist, Prof. Triebel holds a Ph.D. in immunology (Paris University) and successfully developed several research programs in immunogenetics and immunotherapy, leading to 156 publications and 59 patents.
- Pete Meyers
-
Pete Meyers，自2014年2月12日起担任Immutep的非执行董事，并于2017年11月17日被任命为非执行副主席。他曾是KKR投资组合公司Slayback Pharma LLC的首席财务官，直到2023年9月Slayback被出售给Azurity Pharmaceuticals，Inc.。在加入Slayback Pharma LLC之前，Meyers先生曾在Eagle Pharmaceuticals, Inc.、Motif BioSciences Inc.和TetraLogic Pharmaceuticals Corporation担任首席财务官职务。在任职于TetraLogic之前，Meyers先生在医疗保健投资银行领域工作了18年，曾在Dillon，Read & Co.、瑞士信贷 First Boston LLC担任越来越重要的职务，最近还在德意志银行证券公司担任全球医疗保健投资银行业务联席主管。Meyers先生是Thomas M. Brennan Memorial Foundation，Inc.的董事长兼总裁，同时也是East End Hospice，Inc.的副董事长。他获得了波士顿学院的金融理学学士学位和哥伦比亚商学院的工商管理硕士学位。
Pete Meyers has been a Non Executive Director of Immutep since February 12, 2014, and appointed as Non Executive Deputy Chairman on November 17, 2017. He was the Chief Financial Officer of Slayback Pharma LLC, a KKR portfolio company, until Slayback was sold to Azurity Pharmaceuticals, Inc. in September 2023. Prior to joining Slayback Pharma LLC, Mr. Meyers served in Chief Financial Officer roles at Eagle Pharmaceuticals, Inc., Motif BioSciences Inc. and TetraLogic Pharmaceuticals Corporation. Prior to his role at TetraLogic, Mr. Meyers spent 18 years in health care investment banking, holding positions of increasing responsibility at Dillon, Read & Co., Credit Suisse First Boston LLC and, most recently, as Co Head of Global Health Care Investment Banking at Deutsche Bank Securities Inc. He earned a Bachelor of Science degree in Finance from Boston College and a Master of Biness Administration degree from Columbia Biness School. Mr Meyers is currently a Non Executive Director of Yamo Pharmaceuticals LLC, a privately held, development stage company whose molecule, L1 79, is the leading late stage candidate addressing the core social interaction deficits in individuals with autism spectrum disorder. - Pete Meyers，自2014年2月12日起担任Immutep的非执行董事，并于2017年11月17日被任命为非执行副主席。他曾是KKR投资组合公司Slayback Pharma LLC的首席财务官，直到2023年9月Slayback被出售给Azurity Pharmaceuticals，Inc.。在加入Slayback Pharma LLC之前，Meyers先生曾在Eagle Pharmaceuticals, Inc.、Motif BioSciences Inc.和TetraLogic Pharmaceuticals Corporation担任首席财务官职务。在任职于TetraLogic之前，Meyers先生在医疗保健投资银行领域工作了18年，曾在Dillon，Read & Co.、瑞士信贷 First Boston LLC担任越来越重要的职务，最近还在德意志银行证券公司担任全球医疗保健投资银行业务联席主管。Meyers先生是Thomas M. Brennan Memorial Foundation，Inc.的董事长兼总裁，同时也是East End Hospice，Inc.的副董事长。他获得了波士顿学院的金融理学学士学位和哥伦比亚商学院的工商管理硕士学位。
- Pete Meyers has been a Non Executive Director of Immutep since February 12, 2014, and appointed as Non Executive Deputy Chairman on November 17, 2017. He was the Chief Financial Officer of Slayback Pharma LLC, a KKR portfolio company, until Slayback was sold to Azurity Pharmaceuticals, Inc. in September 2023. Prior to joining Slayback Pharma LLC, Mr. Meyers served in Chief Financial Officer roles at Eagle Pharmaceuticals, Inc., Motif BioSciences Inc. and TetraLogic Pharmaceuticals Corporation. Prior to his role at TetraLogic, Mr. Meyers spent 18 years in health care investment banking, holding positions of increasing responsibility at Dillon, Read & Co., Credit Suisse First Boston LLC and, most recently, as Co Head of Global Health Care Investment Banking at Deutsche Bank Securities Inc. He earned a Bachelor of Science degree in Finance from Boston College and a Master of Biness Administration degree from Columbia Biness School. Mr Meyers is currently a Non Executive Director of Yamo Pharmaceuticals LLC, a privately held, development stage company whose molecule, L1 79, is the leading late stage candidate addressing the core social interaction deficits in individuals with autism spectrum disorder.
- Lis Boyce
-
Lis Boyce，自2013年4月11日起担任Immutep的非执行董事。Boyce女士是一名资深企业律师，在融资、战略合作、公司治理和并购方面拥有超过30年的经验。自2021年1月起，她一直担任Piper Alderman公司团队的合伙人，并共同主持该公司的生命科学与医疗保健小组。在加入Piper Alderman之前，她曾在Dentons和DibbsBarker担任各种领导职务。她被任命为ABiotech的AMedtech咨询小组副主席，以及ABiotech的新南威尔士州领导委员会主席，这反映了她对生命科学的强烈关注。Lis是Atralian公司董事研究所的毕业生，也是Atralia治理研究所的研究员。
Lis Boyce has been a Non Executive Director of Immutep since April 11, 2023. Ms Boyce is a senior corporate lawyer with over 30 years' experience including capital raising, strategic collaborations, corporate governance and mergers & acquisitions. She has been a partner in Piper Alderman's corporate team since January 2021, and co chairs the firm's Life Sciences & Healthcare foc group. Prior to Piper Alderman, Lis has held vario leadership roles at Dentons and DibbsBarker. Lis' strong foc on Life Sciences is reflected in her appointment as deputy chair of ABiotech's AMedtech Advisory Group, and as Chair of ABiotech's Leadership Committee for NSW. Lis is a Graduate of the Atralian Institute of Company Directors, and a Fellow of the Governance Institute of Atralia. - Lis Boyce，自2013年4月11日起担任Immutep的非执行董事。Boyce女士是一名资深企业律师，在融资、战略合作、公司治理和并购方面拥有超过30年的经验。自2021年1月起，她一直担任Piper Alderman公司团队的合伙人，并共同主持该公司的生命科学与医疗保健小组。在加入Piper Alderman之前，她曾在Dentons和DibbsBarker担任各种领导职务。她被任命为ABiotech的AMedtech咨询小组副主席，以及ABiotech的新南威尔士州领导委员会主席，这反映了她对生命科学的强烈关注。Lis是Atralian公司董事研究所的毕业生，也是Atralia治理研究所的研究员。
- Lis Boyce has been a Non Executive Director of Immutep since April 11, 2023. Ms Boyce is a senior corporate lawyer with over 30 years' experience including capital raising, strategic collaborations, corporate governance and mergers & acquisitions. She has been a partner in Piper Alderman's corporate team since January 2021, and co chairs the firm's Life Sciences & Healthcare foc group. Prior to Piper Alderman, Lis has held vario leadership roles at Dentons and DibbsBarker. Lis' strong foc on Life Sciences is reflected in her appointment as deputy chair of ABiotech's AMedtech Advisory Group, and as Chair of ABiotech's Leadership Committee for NSW. Lis is a Graduate of the Atralian Institute of Company Directors, and a Fellow of the Governance Institute of Atralia.
- Marc Voigt
-
Marc Voigt， 2012年以来，他曾担任我们的首席财务官和首席商务官。2014年7月他被任命为首席执行官兼执行董事。他在企业和生物技术领域有丰富的经验。他于2011年加入Prima BioMed的主要生物医学的管理团队，并担任Prima BioMed GmbH的我们欧洲业务总经理首席，他目前担任常务董事。他曾担任Allianz Insurance（生物技术风险基金）的投资经理，并担任Allianz Insurance执行委员会成员的私人助理。他也为德国投资银行（German investment bank，net.IPO.AG）工作，负责该地区的业务发展和德国的证券发行。在生物技术领域，他担任Revotar Biopharmaceuticals AG和Medical Enzymes AG的首席财务官和首席商务馆。他获得柏林自由大学（Freie Universitt of Berlin）工商管理硕士学位并且是德国制药许可俱乐部（pharma licensing club Germany）的成员和德国最大的商业计划竞赛评审团成员。
Marc Voigt has been Chief Executive Officer of Immutep since July 9, 2014. He has more than 25 years of experience in the financial and biotech indtry, having joined the Immutep team in 2011 as the General Manager, European Operations based in Berlin, Germany. In 2012, he became Immutep's Chief Biness Officer and Chief Financial Officer and in 2014 he became Immutep's Chief Executive Officer, as ll as continuing to foc on its European operations. Having started his career at the Allianz Group working in pension insurance and funds, he moved to net.IPO AG, a publicly listed boutique investment bank in Frankfurt where he was foced on IPOs and venture capital investments. Marc then worked for a number of years as an investment manager for a midsize venture capital fund based in Berlin, specializing in healthcare. He also gained considerable operational experience while serving in different management roles with Revotar Biopharmaceuticals, Caprotec Bioanalytics and Medical Enzymes AG respectively, where he handled several successful licensing transactions and financing rounds. Since 2001, Marc has been a judge and coach in BPW, Germany's largest regional start up initiative. He is also member of the investment committee of an Atralian venture capital fund. - Marc Voigt， 2012年以来，他曾担任我们的首席财务官和首席商务官。2014年7月他被任命为首席执行官兼执行董事。他在企业和生物技术领域有丰富的经验。他于2011年加入Prima BioMed的主要生物医学的管理团队，并担任Prima BioMed GmbH的我们欧洲业务总经理首席，他目前担任常务董事。他曾担任Allianz Insurance（生物技术风险基金）的投资经理，并担任Allianz Insurance执行委员会成员的私人助理。他也为德国投资银行（German investment bank，net.IPO.AG）工作，负责该地区的业务发展和德国的证券发行。在生物技术领域，他担任Revotar Biopharmaceuticals AG和Medical Enzymes AG的首席财务官和首席商务馆。他获得柏林自由大学（Freie Universitt of Berlin）工商管理硕士学位并且是德国制药许可俱乐部（pharma licensing club Germany）的成员和德国最大的商业计划竞赛评审团成员。
- Marc Voigt has been Chief Executive Officer of Immutep since July 9, 2014. He has more than 25 years of experience in the financial and biotech indtry, having joined the Immutep team in 2011 as the General Manager, European Operations based in Berlin, Germany. In 2012, he became Immutep's Chief Biness Officer and Chief Financial Officer and in 2014 he became Immutep's Chief Executive Officer, as ll as continuing to foc on its European operations. Having started his career at the Allianz Group working in pension insurance and funds, he moved to net.IPO AG, a publicly listed boutique investment bank in Frankfurt where he was foced on IPOs and venture capital investments. Marc then worked for a number of years as an investment manager for a midsize venture capital fund based in Berlin, specializing in healthcare. He also gained considerable operational experience while serving in different management roles with Revotar Biopharmaceuticals, Caprotec Bioanalytics and Medical Enzymes AG respectively, where he handled several successful licensing transactions and financing rounds. Since 2001, Marc has been a judge and coach in BPW, Germany's largest regional start up initiative. He is also member of the investment committee of an Atralian venture capital fund.
- Russell Howard
-
Russell Howard，自2013年5月8日起担任Immutep的非执行董事，并于2017年11月17日被任命为非执行主席。他是澳大利亚科学家、执行经理和企业家。他是分子寄生虫学和“DNA洗牌”商业化的先驱。他是9项专利的发明人，拥有140多项科学出版物。在墨尔本大学获得生物化学博士学位后，他曾在多个研究实验室任职，包括他获得终身职位的美国国立卫生研究院。工业方面，Howard博士曾任职于Schering-Plough位于加利福尼亚州帕洛阿尔托的DNAX研究所；曾任Affymax，Inc.总裁兼科学总监，以及从葛兰素史克分拆出来后的Maxygen, Inc.的联合创始人兼首席执行官，作为Maxygen的首席执行官，Howard博士领导了其在纳斯达克的首次公开募股和二次发行，筹集了2.60亿美元。Maxygen在担任CEO的12年里，开发并合作了数十种技术应用和产品。2008年离开Maxygen后，他创办了清洁技术公司Oakbio Inc.（dBA NovoNutrients），并继续参与美国和澳大利亚的几家创新公司。现任NeuClone Pty Ltd.非执行主席。
Russell Howard has been a Non Executive Director of Immutep since May 8, 2013 and has been appointed as Non Executive Chairman on November 17, 2017. He is an Atralian scientist, executive manager and entrepreneur. He was a pioneer in molecular parasitology and commercialization of "DNA Shuffling". He is an inventor of 9 patents and has over 140 scientific publications. After his PhD in biochemistry from the University of Melbne, he held positions at several research laboratories, including the National Institutes of Health in the A where he gained tenure. In indtry, Dr. Howard worked at Schering Plough's DNAX Research Institute in Palo Alto, CA; was the President and Scientific Director of Affymax, Inc. and co founder and CEO of Maxygen, Inc. After its spin out from Glaxollcome, as Maxygen's CEO, Dr. Howard led its IPO on NASDAQ and a secondary offering, raising $ 260.0 million. Maxygen developed and partnered dozens of technology applications and products over 12 years of his tenure as CEO. After leaving Maxygen in 2008, he started the Cleantech company Oakbio Inc. (dba NovoNutrients) and remains involved in several innovative companies in the A and Atralia. He is currently Non Executive Chairman of NeuClone Pty Ltd. - Russell Howard，自2013年5月8日起担任Immutep的非执行董事，并于2017年11月17日被任命为非执行主席。他是澳大利亚科学家、执行经理和企业家。他是分子寄生虫学和“DNA洗牌”商业化的先驱。他是9项专利的发明人，拥有140多项科学出版物。在墨尔本大学获得生物化学博士学位后，他曾在多个研究实验室任职，包括他获得终身职位的美国国立卫生研究院。工业方面，Howard博士曾任职于Schering-Plough位于加利福尼亚州帕洛阿尔托的DNAX研究所；曾任Affymax，Inc.总裁兼科学总监，以及从葛兰素史克分拆出来后的Maxygen, Inc.的联合创始人兼首席执行官，作为Maxygen的首席执行官，Howard博士领导了其在纳斯达克的首次公开募股和二次发行，筹集了2.60亿美元。Maxygen在担任CEO的12年里，开发并合作了数十种技术应用和产品。2008年离开Maxygen后，他创办了清洁技术公司Oakbio Inc.（dBA NovoNutrients），并继续参与美国和澳大利亚的几家创新公司。现任NeuClone Pty Ltd.非执行主席。
- Russell Howard has been a Non Executive Director of Immutep since May 8, 2013 and has been appointed as Non Executive Chairman on November 17, 2017. He is an Atralian scientist, executive manager and entrepreneur. He was a pioneer in molecular parasitology and commercialization of "DNA Shuffling". He is an inventor of 9 patents and has over 140 scientific publications. After his PhD in biochemistry from the University of Melbne, he held positions at several research laboratories, including the National Institutes of Health in the A where he gained tenure. In indtry, Dr. Howard worked at Schering Plough's DNAX Research Institute in Palo Alto, CA; was the President and Scientific Director of Affymax, Inc. and co founder and CEO of Maxygen, Inc. After its spin out from Glaxollcome, as Maxygen's CEO, Dr. Howard led its IPO on NASDAQ and a secondary offering, raising $ 260.0 million. Maxygen developed and partnered dozens of technology applications and products over 12 years of his tenure as CEO. After leaving Maxygen in 2008, he started the Cleantech company Oakbio Inc. (dba NovoNutrients) and remains involved in several innovative companies in the A and Atralia. He is currently Non Executive Chairman of NeuClone Pty Ltd.
高管简历
中英对照 | 中文 | 英文- Frédéric Triebel
Frédéric Triebel医学博士，Triebel博士是Immutep Limited的首席科学官兼首席医疗官，在完成对Immutep S.A.的收购后，自2014年12月起加入公司。Triebel博士是Immutep S.A.的科学创始人，曾担任Immutep S.A.-2001的科学2004年起任Immutep副院长及医务主任。在创办Immutep公司之前，他是巴黎大学免疫学教授。在巴黎大型癌症中心Gustave Roussy IGR研究所工作期间，他于1990年发现了LAG-3基因，并从那时起继续从事这一研究项目，确定了这一分子的功能和医学用途。他领导了IGR的一个研究小组，同时还参与了在I/II期免疫疗法试验中接受治疗的癌症患者的生物学随访。他在1991年至1996年期间担任一个INSERM股的主任。Triebel教授最初是作为临床血液学家接受培训的，他拥有免疫学博士学位（巴黎大学），并成功开发了免疫遗传学和免疫疗法方面的多个研究项目，导致超过153项出版物和31项专利。
Frédéric Triebel,founded Immutep S.A. in 2001 and served as its Scientific and Medical Director from 2004. He was appointed as Chief Medical Officer and Chief Scientific Officer following the acquisition of Immutep S.A. in December 2014. Prof. Triebel was appointed as a Director on September 13, 2022 and is currently Chief Scientific Officer of the Company. Before starting Immutep S.A., he was Professor in Immunology at Paris University. While working at Institute Gustave Roussy (IGR), a large cancer center in Paris, he discovered the LAG-3 gene in 1990 and continued working on this research program since then, identifying the functions and medical Immutep Limited efulness of this molecule. He headed a research group at IGR while also being involved in the biological follow-up of cancer patients treated in Phase I/II immunotherapy trials. He was Director of an INSERM Unit from 1991 to 1996. First trained as a clinical hematologist, Prof. Triebel holds a Ph.D. in immunology (Paris University) and successfully developed several research programs in immunogenetics and immunotherapy, leading to 156 publications and 59 patents.- Frédéric Triebel医学博士，Triebel博士是Immutep Limited的首席科学官兼首席医疗官，在完成对Immutep S.A.的收购后，自2014年12月起加入公司。Triebel博士是Immutep S.A.的科学创始人，曾担任Immutep S.A.-2001的科学2004年起任Immutep副院长及医务主任。在创办Immutep公司之前，他是巴黎大学免疫学教授。在巴黎大型癌症中心Gustave Roussy IGR研究所工作期间，他于1990年发现了LAG-3基因，并从那时起继续从事这一研究项目，确定了这一分子的功能和医学用途。他领导了IGR的一个研究小组，同时还参与了在I/II期免疫疗法试验中接受治疗的癌症患者的生物学随访。他在1991年至1996年期间担任一个INSERM股的主任。Triebel教授最初是作为临床血液学家接受培训的，他拥有免疫学博士学位（巴黎大学），并成功开发了免疫遗传学和免疫疗法方面的多个研究项目，导致超过153项出版物和31项专利。
- Frédéric Triebel,founded Immutep S.A. in 2001 and served as its Scientific and Medical Director from 2004. He was appointed as Chief Medical Officer and Chief Scientific Officer following the acquisition of Immutep S.A. in December 2014. Prof. Triebel was appointed as a Director on September 13, 2022 and is currently Chief Scientific Officer of the Company. Before starting Immutep S.A., he was Professor in Immunology at Paris University. While working at Institute Gustave Roussy (IGR), a large cancer center in Paris, he discovered the LAG-3 gene in 1990 and continued working on this research program since then, identifying the functions and medical Immutep Limited efulness of this molecule. He headed a research group at IGR while also being involved in the biological follow-up of cancer patients treated in Phase I/II immunotherapy trials. He was Director of an INSERM Unit from 1991 to 1996. First trained as a clinical hematologist, Prof. Triebel holds a Ph.D. in immunology (Paris University) and successfully developed several research programs in immunogenetics and immunotherapy, leading to 156 publications and 59 patents.
- Christian Mueller
Christian Mueller自2024年12月1日起担任首席发展官。在肿瘤药物临床开发领域以不同身份工作了近20年，2016年加入Immutep。穆勒先生曾在不同的生物技术公司的临床开发领域担任过不同的职务，并在临床开发和监管领域带来了广泛的专业知识。他成功地领导了多项临床研究、跨职能团队以及与世界各地主管机构（例如FDA、EMA、PEI、CFDA等）的多场科学建议会议。在柏林工业大学完成生物技术理学硕士学位后，他加入了Medical Enzymes AG，在那里他专注于开发治疗癌症的治疗酶。自2012年起，他与Ganymed Pharmaceuticals AG合作，在免疫肿瘤领域开发理想的单克隆抗体。他曾负责先导抗体（zolbetuximab目前正在EMA/FDA进行BLA/MAA流程）的临床项目，并成功完成了一项涉及200 +名患者的跨国随机IIB期研究，该研究是与安斯泰来12亿D贸易销售协议的核心资产。
Christian Mueller has served as Chief Development Officer since December 1, 2024. He has worked in the field of clinical development of oncology drugs in different roles for almost 2 decades and joined Immutep in 2016. Mr. Mueller worked in different functions in the clinical development sphere at different biotech companies and hass broad expertise in clinical development and the regulatory field. He was leading successfully multiple clinical studies, cross functional teams and multiple scientific advice meetings with competent authorities around the world (e.g. FDA, EMA, PEI, CFDA etc.). After completing his Master of Science in Biotechnology at the Technical University Berlin, he joined Medical Enzymes AG where he foced on developing therapeutic enzymes for the treatment of cancer. Since 2012 he worked with Ganymed Pharmaceuticals AG in developing ideal monoclonal antibodies in the field of immuno oncology. He was responsible for the clinical program of the lead antibody (zolbetuximab now undergoing BLA/MAA process at EMA / FDA) and successfully completed a multinational randomized phase IIb study with 200+ patients which was the core asset of a 1.2 billion D trade sale deal with Astellas.- Christian Mueller自2024年12月1日起担任首席发展官。在肿瘤药物临床开发领域以不同身份工作了近20年，2016年加入Immutep。穆勒先生曾在不同的生物技术公司的临床开发领域担任过不同的职务，并在临床开发和监管领域带来了广泛的专业知识。他成功地领导了多项临床研究、跨职能团队以及与世界各地主管机构（例如FDA、EMA、PEI、CFDA等）的多场科学建议会议。在柏林工业大学完成生物技术理学硕士学位后，他加入了Medical Enzymes AG，在那里他专注于开发治疗癌症的治疗酶。自2012年起，他与Ganymed Pharmaceuticals AG合作，在免疫肿瘤领域开发理想的单克隆抗体。他曾负责先导抗体（zolbetuximab目前正在EMA/FDA进行BLA/MAA流程）的临床项目，并成功完成了一项涉及200 +名患者的跨国随机IIB期研究，该研究是与安斯泰来12亿D贸易销售协议的核心资产。
- Christian Mueller has served as Chief Development Officer since December 1, 2024. He has worked in the field of clinical development of oncology drugs in different roles for almost 2 decades and joined Immutep in 2016. Mr. Mueller worked in different functions in the clinical development sphere at different biotech companies and hass broad expertise in clinical development and the regulatory field. He was leading successfully multiple clinical studies, cross functional teams and multiple scientific advice meetings with competent authorities around the world (e.g. FDA, EMA, PEI, CFDA etc.). After completing his Master of Science in Biotechnology at the Technical University Berlin, he joined Medical Enzymes AG where he foced on developing therapeutic enzymes for the treatment of cancer. Since 2012 he worked with Ganymed Pharmaceuticals AG in developing ideal monoclonal antibodies in the field of immuno oncology. He was responsible for the clinical program of the lead antibody (zolbetuximab now undergoing BLA/MAA process at EMA / FDA) and successfully completed a multinational randomized phase IIb study with 200+ patients which was the core asset of a 1.2 billion D trade sale deal with Astellas.
- Stephan Winckels
Stephan Winckels自2025年7月1日起担任首席医疗官。Winckels博士在肿瘤药物开发方面拥有超过15年的经验。他曾在多种实体瘤和血液系统恶性肿瘤领域为40多项I期III期癌症试验做出贡献。直到2023年，Winckels博士在中型全方位服务CRO Allucent（前身为SMS肿瘤学）领导医疗事务小组和肿瘤医疗团队。Winckels博士还曾在Wyeth Research（现为辉瑞）、Boehringer Ingelheim和GenMAB.Dr.担任肿瘤治疗领域的医学职务。温克尔斯在荷兰马斯特里赫特大学获得医学博士学位。他拥有荷兰乌得勒支大学医学生理学博士学位。他是欧洲医学肿瘤学会的成员。
Stephan Winckels has served as Chief Medical Officer since July 1, 2025. Dr. Winckels has over 15 years of experience in oncology drug development. He has contributed to more than 40 Phase I III cancer trials in a wide variety of solid tumors and hematological malignancies. Until 2023, Dr. Winckels headed the Medical Affairs group and Oncology Medical Team at Allucent (formerly SMS oncology), a mid size full service CRO. Dr. Winckels also held medical positions within the oncology therapeutic area at Wyeth Research (now Pfizer), Boehringer Ingelheim and Genmab.Dr. Winckels obtained his Doctor of Medicine degree at Maastricht University in the Netherlands. He holds a PhD in Medical Physiology from Utrecht University, The Netherlands. He is a member of the European Society for Medical Oncology.- Stephan Winckels自2025年7月1日起担任首席医疗官。Winckels博士在肿瘤药物开发方面拥有超过15年的经验。他曾在多种实体瘤和血液系统恶性肿瘤领域为40多项I期III期癌症试验做出贡献。直到2023年，Winckels博士在中型全方位服务CRO Allucent（前身为SMS肿瘤学）领导医疗事务小组和肿瘤医疗团队。Winckels博士还曾在Wyeth Research（现为辉瑞）、Boehringer Ingelheim和GenMAB.Dr.担任肿瘤治疗领域的医学职务。温克尔斯在荷兰马斯特里赫特大学获得医学博士学位。他拥有荷兰乌得勒支大学医学生理学博士学位。他是欧洲医学肿瘤学会的成员。
- Stephan Winckels has served as Chief Medical Officer since July 1, 2025. Dr. Winckels has over 15 years of experience in oncology drug development. He has contributed to more than 40 Phase I III cancer trials in a wide variety of solid tumors and hematological malignancies. Until 2023, Dr. Winckels headed the Medical Affairs group and Oncology Medical Team at Allucent (formerly SMS oncology), a mid size full service CRO. Dr. Winckels also held medical positions within the oncology therapeutic area at Wyeth Research (now Pfizer), Boehringer Ingelheim and Genmab.Dr. Winckels obtained his Doctor of Medicine degree at Maastricht University in the Netherlands. He holds a PhD in Medical Physiology from Utrecht University, The Netherlands. He is a member of the European Society for Medical Oncology.
- Marc Voigt
Marc Voigt， 2012年以来，他曾担任我们的首席财务官和首席商务官。2014年7月他被任命为首席执行官兼执行董事。他在企业和生物技术领域有丰富的经验。他于2011年加入Prima BioMed的主要生物医学的管理团队，并担任Prima BioMed GmbH的我们欧洲业务总经理首席，他目前担任常务董事。他曾担任Allianz Insurance（生物技术风险基金）的投资经理，并担任Allianz Insurance执行委员会成员的私人助理。他也为德国投资银行（German investment bank，net.IPO.AG）工作，负责该地区的业务发展和德国的证券发行。在生物技术领域，他担任Revotar Biopharmaceuticals AG和Medical Enzymes AG的首席财务官和首席商务馆。他获得柏林自由大学（Freie Universitt of Berlin）工商管理硕士学位并且是德国制药许可俱乐部（pharma licensing club Germany）的成员和德国最大的商业计划竞赛评审团成员。
Marc Voigt has been Chief Executive Officer of Immutep since July 9, 2014. He has more than 25 years of experience in the financial and biotech indtry, having joined the Immutep team in 2011 as the General Manager, European Operations based in Berlin, Germany. In 2012, he became Immutep's Chief Biness Officer and Chief Financial Officer and in 2014 he became Immutep's Chief Executive Officer, as ll as continuing to foc on its European operations. Having started his career at the Allianz Group working in pension insurance and funds, he moved to net.IPO AG, a publicly listed boutique investment bank in Frankfurt where he was foced on IPOs and venture capital investments. Marc then worked for a number of years as an investment manager for a midsize venture capital fund based in Berlin, specializing in healthcare. He also gained considerable operational experience while serving in different management roles with Revotar Biopharmaceuticals, Caprotec Bioanalytics and Medical Enzymes AG respectively, where he handled several successful licensing transactions and financing rounds. Since 2001, Marc has been a judge and coach in BPW, Germany's largest regional start up initiative. He is also member of the investment committee of an Atralian venture capital fund.- Marc Voigt， 2012年以来，他曾担任我们的首席财务官和首席商务官。2014年7月他被任命为首席执行官兼执行董事。他在企业和生物技术领域有丰富的经验。他于2011年加入Prima BioMed的主要生物医学的管理团队，并担任Prima BioMed GmbH的我们欧洲业务总经理首席，他目前担任常务董事。他曾担任Allianz Insurance（生物技术风险基金）的投资经理，并担任Allianz Insurance执行委员会成员的私人助理。他也为德国投资银行（German investment bank，net.IPO.AG）工作，负责该地区的业务发展和德国的证券发行。在生物技术领域，他担任Revotar Biopharmaceuticals AG和Medical Enzymes AG的首席财务官和首席商务馆。他获得柏林自由大学（Freie Universitt of Berlin）工商管理硕士学位并且是德国制药许可俱乐部（pharma licensing club Germany）的成员和德国最大的商业计划竞赛评审团成员。
- Marc Voigt has been Chief Executive Officer of Immutep since July 9, 2014. He has more than 25 years of experience in the financial and biotech indtry, having joined the Immutep team in 2011 as the General Manager, European Operations based in Berlin, Germany. In 2012, he became Immutep's Chief Biness Officer and Chief Financial Officer and in 2014 he became Immutep's Chief Executive Officer, as ll as continuing to foc on its European operations. Having started his career at the Allianz Group working in pension insurance and funds, he moved to net.IPO AG, a publicly listed boutique investment bank in Frankfurt where he was foced on IPOs and venture capital investments. Marc then worked for a number of years as an investment manager for a midsize venture capital fund based in Berlin, specializing in healthcare. He also gained considerable operational experience while serving in different management roles with Revotar Biopharmaceuticals, Caprotec Bioanalytics and Medical Enzymes AG respectively, where he handled several successful licensing transactions and financing rounds. Since 2001, Marc has been a judge and coach in BPW, Germany's largest regional start up initiative. He is also member of the investment committee of an Atralian venture capital fund.
- Deanne Miller
Deanne Miller，2012年10月加入Immutep，担任总法律顾问和公司秘书，2016年11月晋升为首席运营官。她拥有广泛的商业经验，曾担任法律、投资银行、监管合规和税务咨询职位，包括，加拿大皇家银行投资者服务公司法律顾问、西太平洋银行集团副董事、麦格理集团法律与合规经理、澳大利亚证券和投资委员会监管合规分析师以及毕马威会计师事务所税务顾问。她拥有悉尼大学的法学（荣誉）和商业、会计和金融（双专业）双学士学位。她被新州录取为律师，也是新州法律协会的成员。
Deanne Miller joined Immutep as General Counsel and Company Secretary in October 2012 and was promoted to the role of Chief Operating Officer in November 2016. She has broad commercial experience, having held legal, investment banking, regulatory compliance and tax advisory positions, including, Legal Counsel at RBC Investor Services, Associate Director at stpac Group, Legal & Compliance Manager at Macquarie Group, Regulatory Compliance Analyst at the Atralian Securities and Investment Commission, and Tax Advisor at KPMG. She has a Combined Bachelor of Laws (Honors) and Bachelor of Commerce, Accounting and Finance (double major) from the University of Sydney. She is admitted as a solicitor in NSW and member of the Law Society of NSW.- Deanne Miller，2012年10月加入Immutep，担任总法律顾问和公司秘书，2016年11月晋升为首席运营官。她拥有广泛的商业经验，曾担任法律、投资银行、监管合规和税务咨询职位，包括，加拿大皇家银行投资者服务公司法律顾问、西太平洋银行集团副董事、麦格理集团法律与合规经理、澳大利亚证券和投资委员会监管合规分析师以及毕马威会计师事务所税务顾问。她拥有悉尼大学的法学（荣誉）和商业、会计和金融（双专业）双学士学位。她被新州录取为律师，也是新州法律协会的成员。
- Deanne Miller joined Immutep as General Counsel and Company Secretary in October 2012 and was promoted to the role of Chief Operating Officer in November 2016. She has broad commercial experience, having held legal, investment banking, regulatory compliance and tax advisory positions, including, Legal Counsel at RBC Investor Services, Associate Director at stpac Group, Legal & Compliance Manager at Macquarie Group, Regulatory Compliance Analyst at the Atralian Securities and Investment Commission, and Tax Advisor at KPMG. She has a Combined Bachelor of Laws (Honors) and Bachelor of Commerce, Accounting and Finance (double major) from the University of Sydney. She is admitted as a solicitor in NSW and member of the Law Society of NSW.